GlassScriptPhysician profile
Earl S Golightly
NPI 1366481848
$555.21
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $159 · 2021: $142 · 2022: $90.63.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $182.91 | 2019-2021 | |
| Merz North America, INC. | $90.28 | 2020-2021 | |
| Genzyme Corporation | $54.92 | 2019-2022 | |
| Aerin Medical INC. | $44.65 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $36.34 | 2021 | |
| Optinose US, INC. | $35.00 | 2020 | |
| Medtronic USA, INC. | $26.37 | 2019 | |
| Abbvie INC. | $22.38 | 2022 | |
| Stryker Corporation | $21.19 | 2020 | |
| Alk-Abello, INC | $16.90 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.57 | 2019 | |
| Glaxosmithkline, LLC. | $11.70 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earl Golightly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.